The Envelope (E) Protein of SARS-CoV-2 as a Pharmacological Target
The COVID-19 pandemic caused by the SARS-CoV-2 virus is still a global health concern. Several spike (S) protein-based vaccines have been developed that efficiently protect the human population against severe forms of COVID-19. However, some SARS-CoV-2 variants of concern (VOCs) have emerged that ev...
Main Author: | Teresa Santos-Mendoza |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-04-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/15/4/1000 |
Similar Items
-
Peptide Targeting of PDZ-Dependent Interactions as Pharmacological Intervention in Immune-Related Diseases
by: Luis H. Gutiérrez-González, et al.
Published: (2021-10-01) -
Identification of Host PDZ-Based Interactions with the SARS-CoV-2 E Protein in Human Monocytes
by: Antonia Ávila-Flores, et al.
Published: (2023-08-01) -
Receptor-Loaded Virion Endangers GPCR Signaling: Mechanistic Exploration of SARS-CoV-2 Infections and Pharmacological Implications
by: Qiangmin Zhang, et al.
Published: (2021-10-01) -
SARS-CoV-2 Nucleocapsid Protein Is a Potential Therapeutic Target for Anticoronavirus Drug Discovery
by: Austin Royster, et al.
Published: (2023-06-01) -
Interactions of Severe Acute Respiratory Syndrome Coronavirus 2 Protein E With Cell Junctions and Polarity PSD-95/Dlg/ZO-1-Containing Proteins
by: Yanlei Zhu, et al.
Published: (2022-02-01)